Factors influencing non-approval of new drugs in Europe

Nature Reviews Drug Discovery

Volumn 11, Issue 12, 2012, Pages 903-904

  Putzeist, Michelle ^a   Mantel Teeuwisse, Aukje K ^b   Aronsson, Bo ^c   Rowland, Malcolm ^d   Gispen De Wied, Christine C ^b   Vamvakas, Spiros ^c   Hoes, Arno W ^e   Leufkens, Hubert G M ^a   Eichler, Hans Georg ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c EUROPEAN MEDICINES AGENCY   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DRONEDARONE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; NEW DRUG; PIRFENIDONE; PLERIXAFOR;

DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; EUROPE; FIBROSING ALVEOLITIS; HEART ATRIUM FIBRILLATION; HEMATOPOIETIC STEM CELL; LUNG NON SMALL CELL CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STEM CELL MOBILIZATION;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; EUROPE; HUMANS; LOGISTIC MODELS;

EID: 84870786837     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3894     Document Type: Review

References (2)

1. Eichler, H. G. et al. New drug approval success rate in Europe in 2009. Nature Rev. Drug Discov. 9, 355-356 (2010).
2. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203-214 (2010).